From: Current controversies in radiotherapy for breast cancer
MA.20 [10] | EORTC 22922/10925 [9] | DBCG-IMN [35] | French trial [36] | |||||
---|---|---|---|---|---|---|---|---|
Study design | Phase III randomized controlled trial | Phase III randomized controlled trial | Prospective cohort study | Phase III randomized controlled trial | ||||
Treatment arms | WBI + boost | WBI + boost + SCV/IMN | WBI + Boost TWI | WBI + boost + SCV/IMN TWI + SCV/IMN | WBI + Boost + SCV (left sided tumor location) | WBI + Boost + SCV/IMN (right sided tumor location) | TWI + SCV | TWI + SCV/IMN |
Inclusion criteria | N+ or N0 high risk (T3 or T2 with < 10 lymph resected lymph nodes and additional risk factors present) | N+ or N0 (medial or central tumor location) | N+ | N+ or N0 (medial or central tumor location) | ||||
Number of patients | 1832 | 4004 | 3089 | 1334 | ||||
Recruitment period | 2000–2007 | 1996–2004 | 2003–2007 | 1991–1997 | ||||
Median follow up | 9.5 years | 10.9 years | 8.9 years | 8.6 years | ||||
Disease-free survival | 77.0% | 82.0% | 69.1% | 72.1% | n.s. | 49.9% | 53.2% | |
p = 0.01; HR 0.76 (95% CI 0.61–0.94) | p = 0.04; HR 0.89 (95% CI 0.80–1.00) | p = 0.35 | ||||||
Overall survival | 81.8% | 82.8% | 80.7% | 82.3% | 72.2% | 75.9% | 59.3% | 62.6% |
p = 0.38; HR 0.91 (95%-CI 0.72–1.13) | p = 0.06; HR 0.87 (95%-CI 0.76–1.00) | p = 0.005; HR 0.82 (95%–CI 0.72–0.94) | p = 0.8 |